دورية أكاديمية
Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals.
| العنوان: | Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. |
|---|---|
| المؤلفون: | Aneni EC; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States of America., Saeed GJ; Center for Sleep and Cardiovascular Outcomes Research, University of Pittsburgh, Pittsburgh, PA, United States of America., Bittencourt MS; Center for Clinical and Epidemiological Research, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São Paulo, São Paulo, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil., Cainzos-Achirica M; Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States of America.; Center for Outcomes Research, Houston Methodist Research Institute, Houston, TX, United States of America., Osondu CU; Baptist Health South Florida, Miami, FL, United States of America., Budoff M; The Lundquist Institute for Biomedical Innovation, Los Angeles, CA, United States of America.; David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America., Parise ER; Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil., Santos RD; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Lipid Clinic Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil., Nasir K; Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States of America.; Center for Outcomes Research, Houston Methodist Research Institute, Houston, TX, United States of America. |
| المصدر: | PloS one [PLoS One] 2022 Apr 06; Vol. 17 (4), pp. e0266505. Date of Electronic Publication: 2022 Apr 06 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
| مواضيع طبية MeSH: | Alcoholism*/complications , Hypertension*/complications , Non-alcoholic Fatty Liver Disease*/metabolism, Blood Glucose ; Body Mass Index ; C-Reactive Protein ; Humans ; Incidence ; Inflammation/complications ; Longitudinal Studies ; Risk Factors |
| مستخلص: | Background: There is limited knowledge about the risk of non-alcoholic fatty liver disease (NAFLD) associated with cardiometabolic disorders in lean persons. This study examines the contribution of cardiometabolic disorders to NAFLD risk among lean individuals and compares to non-lean individuals. Methods: We analyzed longitudinal data from 6,513 participants of a yearly voluntary routine health testing conducted at the Hospital Israelita Albert Einstein, Brazil. NAFLD was defined as hepatic ultrasound diagnosed fatty liver in individuals scoring below 8 on the alcohol use disorders identification test. Our main exposure variables were elevated blood glucose, elevated blood pressure (BP), presence of atherogenic dyslipidemia (AD, defined as the combination of elevated triglycerides and low HDL cholesterol) and physical inactivity (<150 minutes/week of moderate activity). We further assessed the risk of NAFLD with elevations in waist circumference and high sensitivity C-reactive protein (HsCRP). Results: Over 15,580 person-years (PY) of follow-up, the incidence rate of NAFLD was 7.7 per 100 PY. In multivariate analysis adjusting for likely confounders, AD was associated with a 72% greater risk of NAFLD (IRR: 1.72 [95% CI:1.32-2.23]). Elevated blood glucose (IRR: 1.71 [95%CI: 1.29-2.28]) and physical inactivity (IRR: 1.46 [95%CI: 1.28-1.66]) were also independently associated with increased risk of NAFLD. In lean individuals, AD, elevated blood glucose and elevated BP were significantly associated with NAFLD although for elevated blood glucose, statistical significance was lost after adjusting for possible confounders. Physical inactivity and elevations in HsCRP were not associated with the risk of NAFLD in lean individuals only. Among lean (and non-lean) individuals, there was an independent association between progressively increasing waist circumference and NAFLD. Conclusion: Cardiometabolic risk factors are independently associated with NAFLD. However, there are significant differences in the metabolic risk predictors of NAFLD between lean and non-lean individuals. Personalized cardiovascular disease risk stratification and appropriate preventive measures should be considered in both lean and non-lean individuals to prevent the development of NAFLD. Competing Interests: The authors have declared that no competing interests exist. |
| References: | Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. (PMID: 29908364) Nutrients. 2013 May 10;5(5):1544-60. (PMID: 23666091) Hepatology. 2018 May;67(5):1726-1736. (PMID: 28941364) Circulation. 2005 Feb 8;111(5):697-716. (PMID: 15699287) Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. (PMID: 23507799) Medicine (Baltimore). 2012 Nov;91(6):319-327. (PMID: 23117851) Hepatology. 2011 Sep 2;54(3):1082-1090. (PMID: 21618575) Metabolism. 2019 Mar;92:82-97. (PMID: 30502373) J Gastroenterol Hepatol. 2018 Mar;33(3):741-746. (PMID: 28857324) Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63. (PMID: 17605315) Atherosclerosis. 2015 Apr;239(2):629-33. (PMID: 25683387) Hepatol Int. 2019 May;13(3):314-322. (PMID: 30539516) Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. (PMID: 31028350) J Ultrasound Med. 1984 Jan;3(1):9-14. (PMID: 6694259) Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365) Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. (PMID: 28930295) Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50. (PMID: 22245962) Liver Int. 2017 Nov;37(11):1715-1722. (PMID: 28544258) Am J Epidemiol. 2013 Jul 1;178(1):38-45. (PMID: 23703888) J Hepatol. 2009 Dec;51(6):1061-7. (PMID: 19846234) J Hepatol. 2017 Feb;66(2):390-397. (PMID: 27729222) Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E1033-9. (PMID: 21846904) World J Gastroenterol. 2017 Sep 28;23(36):6571-6592. (PMID: 29085206) Dig Dis Sci. 2013 Oct;58(10):3017-23. (PMID: 23775317) Clin Diabetes. 2019 Jan;37(1):65-72. (PMID: 30705499) Hepatology. 2012 Jun;55(6):2005-23. (PMID: 22488764) Clin Gastroenterol Hepatol. 2016 Feb;14(2):301-8.e1-2. (PMID: 26291667) Alcohol Clin Exp Res. 1997 Jun;21(4):613-9. (PMID: 9194913) Semin Liver Dis. 2019 Feb;39(1):86-95. (PMID: 30654392) Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. (PMID: 32413340) |
| معلومات مُعتمدة: | KL2 TR001862 United States TR NCATS NIH HHS |
| المشرفين على المادة: | 0 (Blood Glucose) 9007-41-4 (C-Reactive Protein) |
| تواريخ الأحداث: | Date Created: 20220406 Date Completed: 20220414 Latest Revision: 20240228 |
| رمز التحديث: | 20240228 |
| مُعرف محوري في PubMed: | PMC8985996 |
| DOI: | 10.1371/journal.pone.0266505 |
| PMID: | 35385529 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!